Urokinase-type plasminogen activator expression in human prostate carcinomas

American Journal of the Medical Sciences

Volumn 312, Issue 1, 1996, Pages 8-11

  Van Veldhuizen, Peter J ^a   Sadasivan, Raj ^b   Cherian, Rachel ^b   Wyatt, Angel ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Invasion; Monoclonal antibody 394; Prostate; Urokinase

Indexed keywords

MONOCLONAL ANTIBODY; UROKINASE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE CARCINOMA; PROSTATECTOMY;

EID: 0029980844     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199607000-00002     Document Type: Article

References (29)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin. 1996;65:5-27.
2. Liotta LA, Kohn E. Cancer invasion and metastases. JAMA. 1990;263:1123-6.
3. Eisenbarth L. Proteolytic enzymes in tumor metastases I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma. J Natl Cancer Inst. 1985;74:77-85.
4. Carlson J. Involvement of plasminogen activator production with tumor metastasis in a rat model. Cancer Res. 1984;44:3012-16.
5. Gaylis FD, Keer HN, Wilson MJ, Kwaan HC, Sinha AA, Kozlowski JM. Plasminogen activators in human prostate cancer cell lines and tumors: Correlation with the aggressive phenotype. J Urol. 1989;142:193-8.
6. Gris JC, Schved JF, Marty-Double C, Mauboussin JM, Balmes P. Immunohistochemical study of tumor cell-associated plasminogen activator and plasminogen activator inhibitor in lung carcinomas. Chest. 1993;104:8-13.
7. Grondahl-Hansen J, Ralfkiaer E, Kirkeby LT, Kristensen P, Lund LR, Dano K. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinoma of the colon in humans. Am J Pathol. 1991;138:111-17.
8. Pujade-Lauraine E, Lu H, Mirshahi S, Soria C, Bernadou A, Kruithof EKO. The plasminogen-activation system in ovarian tumors. Int J Cancer. 1993;55:27-31.
9. de Vries TJ, Quax P, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, et al. Plasminogen activators, their inhibitors and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol. 1994;144,70-81.
10. Gleeson N, Gonsalves R, Bonnar J. The plasminogen activator urokinase and its inhibitor PAI-2 in endometrial cancer. Gynecol Oncol. 1992;47:58-61.
11. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res. 1994;54:2900-7.
12. Janicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, et al. Urokinase-type plasminogen activator(u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis. 1990;4:69-78.
13. Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H, et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat. 1993;24:195-208.
14. Duffy MJ, Reilly D, Nolan N, O'Higgins N, Fennelly JJ, Andreasen P. Urokinase plasminogen activator, a strong and independent prognostic marker in beast cancer. Fibrinolysis. 1992;4(Suppl 6):55-7.
15. Sumiyoshi K, Baba S, Sakaguchi S, Urano T, Takada Y, Takada A. Increase in levels of plasminogen activator and type-1 plasminogen inhibitor in human breast cancer. Thromb Res. 1991;63:59-71.
16. Duffy MJ, Reilly D, McDermott E, O'Higgins NO, Fennelly JJ, Andreasen A. Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer. 1994;74:2276-80.
17. Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Janicke F, et al. Prognostic value of urokinasetype plasminogen activator in 671 primary breast cancer patients. Cancer Res. 1992;52:6101-5.
18. Grondahl-Hansen J, Christensen J, Rosenquist C, Brunner N, Mouridsen HT, Dano K, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in Cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993;53:2513-21.
19. Hoosein NM, Boyd DD, Hollas WJ, Mazar A, Henkin J, Chung LWK. Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Communications. 1991;3:255-64.
20. Kwaan HC, Keer HN, Radosevich JA, Cajot JF, Ernst R. Components of the plasminogen-plasmin system in human tumor cell lines. Semin Thromb Hemost. 1991;17:175-81.
21. Camiolo SM, Markus G, Englander LS, Siuta MR, Hobika GH, Kohga S. Plasminogen activator content and secretion in expiants of neoplastic and benign human prostate tissues. Cancer Res. 1984;44:311-18.
22. Heinert G, Kirchheimer JC, Pfluger H, Binder BR. Urokinase-type plasminogen prostatic activator as a marker for the formation of distant metastases in prostatic carcinomas. J Urol. 1988;140:1466-9.
23. Heinert G, Kirchheimer JC, Christ G, Pfluger H, Binder BR. Plasma urokinase-type plasminogen activator correlated to bone scintigraphy in prostatic carcinoma. Eur Urol. 1988;15: 256-8.
24. Stein PM, Stass SA, Kagan J. The human urokinase-plasminogen activator gene (PLAU) is located on chromosome 10q24 centromeric to the HOX11 gene. Genomics. 1993;16:301-2.
25. Collins VP, Kunimi K, Bergerheim U, Ekman P. Molecular genetics and human prostate carcinoma. Acta Oncologica. 1991;30:181-5.
26. Sakr WA, Macoska JA, Benson P, Grignon DJ, Wolman SR, Pontes JE, et al. Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res. 1994;54:3273-7.
27. Sadasivan R, Van Veldhuizen P, Horvat B, Dwyer T, Kimura M, Austenfeld M, et al. Deletions of the genes for plasminogen activators uPA and tPA in human prostate carcinoma. Proceedings of the American Association of Cancer Research. 1993;34:194.
28. Koutsilieris M. Osteoblastic metastasis in advanced prostate cancer. Anticancer Res. 1993;13:443-50.
29. Achbarou A, Kaiser S, Tremblay G, Ste-Marie L, Brodt P, Goltzman D, et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res. 1994:54;2372-7.